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Abstract
At present there is consent that patients with acute pulmonary embolism (APE) and
hemodynamic instability have poor prognosis and benefit from thrombolytic therapy or embolec-
tomy, whereas hemodynamically stable patients without echocardiographic signs of right ven-
tricular overload/dysfunction (RVO) have good prognosis and should be treated with anticoagu-
lation alone. The optimal treatment for stable APE patients with RVO remains a challenge, and
cardiac biomarkers can probably add to risk stratification and therapeutic decision making.
Troponins are indicators of irreversible cardiac cell injury, and in patients with APE even
a moderate rise of the blood troponin level correlates with RVO, hemodynamic instability and
cardiogenic shock. However, the positive predictive value of cardiac troponins is relatively low.
It can be increased when the results of troponins and echocardiography are combined. The
clinical benefits of cardiac troponins result foremost from the high negative predictive value of
in-hospital events, including death. Likewise, elevated levels of natriuretic peptides such as
BNP and NT-proBNP, caused by increased right ventricular stress, show close association
with RVO and with increased in-hospital risk. Instead, the low level of natriuretic biomarkers
indicates an uncomplicated outcome of APE.
There are some proposals of algorithms that combine both biomarkers and echocardiography
for risk stratification. The principal aim of ongoing studies is to find patients with
hemodynamically stable APE who can be candidates for thrombolytic therapy. The usefulness
of biomarkers in long-term prognosis and their value to identify APE patients in whom
chronic thromboembolic pulmonary hypertension can develop should also be confirmed.
(Cardiol J 2008; 15: 17–20)
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Introduction
At present, the assessment of patient hemo-
dynamic status, and echocardiography in stable pa-
tients, have been the most important prognostic
factors of acute pulmonary embolism (APE). How-
ever, risk stratification based on echocardiography
has proved to be unsatisfactory. Right ventricular
dilation, hypokinesis, flattening, paradoxical move-
ment of interventricular septum, as well as in-
creased end-diastolic dimension and tricuspid insuf-
ficiency are considered the most typical echocardi-
ographic features of right ventricular overload/
/dysfunction (RVO). Demonstrating RVO in hemo-
dynamically stable APE patients classifies them into
the submassive APE category, which has a worse
prognosis than non-massive APE, i.e. without RVO
features; however, the presence of RVO does not
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have enough discriminative force for the decision
process of thrombolysis initiation.
Recently cardiac biomarkers were suggested
for risk determination and therapeutic method se-
lection in APE patients. Two biomarker groups have
been extensively studied: myocardial damage
(necrosis) indicators and neurohormonal activation
indicators.
Prognostic role of myocardial necrosis
indicators in patients with
acute pulmonary embolism
Myocardial damage markers, which allow diag-
nosis of even minor myocardial injury such as car-
diac troponin T and I, mioglobin, CPK-MB (MB frac-
tion of phosphocreatine kinase), have already been
used for ischemic heart disease, left ventricular fail-
ure and myocarditis diagnosis and prognosis. Their
usefulness in new indications is based on their ca-
pability of indication of myocardial necrosis regard-
less of causative mechanism. In APE, myocardial
necrosis may be due to right ventricular infarction,
which may be secondary to APE or may accompa-
ny this condition [1, 2] even if coronary arteries
show no pathology [3]. During an APE incident,
CPK-MB serum activity and cardiac troponins I and
T level increase were demonstrated; an increase of
mioglobin level was reported to occur even before
CPK-MB and troponins [4]. Recent reports indicate
that the new myocardial necrosis marker, h-FABP
(heart fatty acid binding protein), may also be
a promising indicator of early cardiac injury and
a marker of early risk in APE superior to troponins
and mioglobin [5, 6].
Troponins, widely used biomarkers of irrevers-
ible myocardial damage, are highly sensitive and
specific. They are released into the bloodstream in
large amounts during myocardial infarction, and
elevated levels of these can be found in serum over
seven days even in non-ST elevation acute coronary
syndromes [7]. However, in APE, troponin level
increase is mild, may occur from 6 to 12 hours af-
ter acute embolic incident and is transient, usually
lasting no longer than 2–3 days [8]. Troponin in-
crease is known to occur in hemodynamically un-
stable, massive acute pulmonary embolism and has
prognostic relevance [9, 10]. However, from a clin-
ical point of view, the determination of troponin
levels in massive APE has no therapeutic implica-
tions because all patients with this condition require
fibrinolysis or embolectomy anyway. Nevertheless,
troponin level determination may be relevant in
hemodynamically stable APE. A good correlation
between troponin levels and echocardiographical
features of RVO has been repeatedly demonstrat-
ed in this disease [11]. Pruszczyk et al. [12] report-
ed an elevated troponin T level > 0.01 ng/mL to be
the only parameter to predict adverse events in
a 15-day in-hospital period, and all eight deaths
occurred in patients with positive troponin tests.
What is even more clinically relevant, the negative
result of troponin test was demonstrated to predict
uncomplicated disease course [13]. This was shown
in the largest study yet (Mappet 3) comparing anti-
coagulation and fibrinolysis in 106 patients with sta-
ble, submassive APE [14]. In acute coronary syn-
drome, serum troponin level increase is a recog-
nized risk factor which necessitates invasive
therapy.
Neurohormonal activation indicators
in risk stratification of acute
pulmonary embolism patients
Indicators of neurohormonal activation, includ-
ing the most widely known active natriuretic pep-
tide BNP, which is released into peripheral blood
by cardiomyocytes and has a short half-life (23 min)
and inactive N-terminal pro-brain natriuretic pep-
tide (NT-proBNP) with 5-times longer half-life,
seem to have a significant prognostic value in APE.
The role of natriuretic peptides in differential diag-
nosis of cardiac and extracardiac dyspnea has been
proved in many trials [15]. Determination of BNP
has a high prognostic value, mostly in heart failure
[16]. The first report of BNP elevation in serum
from a patient with APE was published in 1997 [17].
Four years later, Tulevski et al. [18] demonstrated
that elevated BNP levels can be found in APE pa-
tients who present echocardiographical RVO fea-
tures. Kucher et al.  [19], who measured BNP con-
centration in 73 APE patients, showed that most
patients who died or required therapy intensifica-
tion during hospitalization had elevated serum BNP.
However, the cutoff value to diagnose 95% patients
with mild disease course was not < 90 pg/mL
(which is required to exclude left ventricular failure)
but was < 50 pg/mL. In studies by Pieralli et al. [20],
a BNP level of < 85 pg/mL was shown to exclude
echocardiographical findings of RVO in 61 normo-
tensive patients with first APE incident with a high
degree of accuracy. However, all patients with BNP
over 527 pg/mL revealed RVO features in echocar-
diography; all acute complications and deaths oc-
curred in this patient group. The role of the BNP
precursor, NT-proBNP, in short-term risk predic-
tion in APE patients has also been established.
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In studies by Pruszczyk et al. [21], who assessed
79 patients with hemodynamically stable and unsta-
ble APE, an increase of NT-proBNP was found in
all patients with massive APE, and those who pre-
sented RVO in echocardiography and who died or
developed other in-hospital adverse effects showed
significantly higher concentrations of this marker.
NT-proBNP levels also correlated with echocardi-
ographic evidence of RVO.
Suggested risk stratification algorithms
in acute pulmonary embolism
with use of cardiac biomarkers
Kucher et al. [22], who analyzed pro-BNP in
APE patients, demonstrated that low levels, i.e.
< 500 ng/mL, are prognostic of an uncomplicated
in-hospital course, and troponin and NT-proBNP
were complementary in short-term risk assessment
in this patient group. Increase of troponin level was
diagnostic for patients at risk of death and serious
complications, while low proBNP levels were char-
acteristic for low-risk patients who could be man-
aged as outpatients. These were the grounds for
a practical risk stratification algorithm, according to
which patients with unstable APE do not require
biomarker determination (nor echocardiography)
since they require thrombolysis irrespectively of
the results. Patients with hemodynamically stable
APE and normal levels of both biomarkers are clas-
sified as low complication risk. These patients need
no routine echocardiography, since almost all of
them have normal right ventricular function. On the
other hand, hemodynamically stable patients with
elevated biomarker levels should have echocardio-
graphy performed due to high probability of RVO
— if confirmed, these patients are at significant risk,
and fibrinolysis should be considered [23]. Kostur-
biec et al. [24] also studied risk stratification of APE
patients by measuring troponin T and NT-proBNP
and performing echocardiography in 100 initially
stable APE patients. This procedure allowed the
identification patients with high risk of fatal com-
plications in 40-day follow-up (elevated troponin
> 0.07 mg/L and elevated NT-proBNP ≥ 600 ng/L).
However, the prognosis for patients with NT-proBNP
of < 600 ng/mL was good.
Cardiac biomarkers in long-term
prognosis in acute pulmonary
embolism patients
It has been observed that the determination of
biomarkers during acute embolic incident may have
some prognostic value in the long-term. In a trial
by Wolde et al. [25], baseline BNP < 21.7 pmol/L
(75 pg/mL) was related to mortality, not only APE-
-related, but all-cause. Risk of 3-month death was
17% (95% CI 6–33%) and BNP < 21.7 pmol/L
(which equals 75 pg/mL) had a significant negative
prognostic value of 99% (95% CI 93–100%).
Tulevski et al. [26], who measured BNP and
troponin T in 28 normotensive APE patients,
confirmed that patients with elevated BNP (204 ±
± 104 pg/mL), troponin T (0.044 ± 0.025 ng/mL)
at baseline and echocardiographical features of RVO
were at risk of death. However, from eight patients
with elevated BNP at baseline and normal troponin
T level, in four cases systolic right ventricular pres-
sure of > 40 mm Hg persisted 90 days after the in-
cident, allowing chronic thromboembolic pulmonary
hypertension to be diagnosed. The follow-up BNP
of these patients remained elevated, i.e. 162.2 ±
± 72 pg/mL.
Therefore, biomarker determination in stable
APE patients appears to be a valuable diagnostic
adjunct, and in some cases may even substitute
echocardiography in in-hospital and long-term risk
stratification. One should emphasize the work of
Polish researchers, namely Piotr Pruszczyk and
Adam Torbicki, and their contribution to the under-
standing of this issue. In future we will probably
discover whether the determination of biomarkers
will be able to help solve one of the most urgent
therapeutic problems of APE — the selection of
stable patients for fibrinolysis. Hopefully their role
in the prognosis of chronic thromboembolic pulmo-
nary hypertension development following APE will
also be established.
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